Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2013-02-22

FDA Approved: TAFLUPROST OPHTHALMIC — Supplemental Application (Prasco Laboratories)

View source ↗

Summary

FDA supplemental application for Tafluprost Ophthalmic submitted by Prasco Laboratories, likely seeking changes to the product labeling. This involves updating …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TAFLUPROST OPHTHALMIC (TAFLUPROST)

Snippet

SUPPL AP for TAFLUPROST OPHTHALMIC (TAFLUPROST)